ENHANCED PROVIDES BUSINESS UPDATE

Rhea-AI Summary

Enhanced (APAD) launched a personalized performance medicine and supplement platform on March 18, 2026, debuting proprietary Stronger and Longer supplement lines plus performance and longevity protocols for men and women. The platform currently offers the peptide Sermorelin and plans further peptide expansion tied to potential FDA reclassification.

The company sponsors an IRB-approved clinical trial of 40 elite athletes to generate proprietary data for product personalization. Management highlighted a peptide market opportunity of $52B today to $87B by 2035 as a revenue catalyst.

Positive

• Platform launch with Stronger & Longer supplement lines
• IRB-approved clinical trial studying 40 elite athletes
• Sermorelin peptide available at platform launch
• Global peptide market estimated at $52B today, $87B by 2035

Negative

• Peptide expansion contingent on regulatory reclassification to Category 1
• Commercial rollout timing depends on regulatory approvals and compounding allowances
• Initial peptide offering currently limited to Sermorelin

News Market Reaction – APAD

-0.10%

1 alert

-0.10% News Effect

On the day this news was published, APAD declined 0.10%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Peptides potentially reclassified: 14 compounds Peptide therapeutics market: $52 billion Peptide market projection: $87 billion +2 more

5 metrics

Peptides potentially reclassified 14 compounds Indications of move from FDA Category 2 to Category 1

Peptide therapeutics market $52 billion Current estimated global market size

Peptide market projection $87 billion Projected global market size by 2035

Clinical trial participants 40 elite athletes IRB-approved trial assessing safety and tolerability

Inaugural event date May 24, 2026 Enhanced Games event tied to clinical trial

Market Reality Check

Price: $10.16 Vol: Volume 38,809 is below 20...

normal vol

$10.16 Last Close

Volume Volume 38,809 is below 20-day average 46,627 (relative volume 0.83). normal

Technical Price 10.16 is trading above 200-day MA 10.02 and near 52-week high 10.21.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Athlete participation update	Positive	+0.0%	Non-enhanced Olympian Tristan Evelyn added to inaugural Enhanced Games sprint field.
Mar 04	Sponsorship partnership	Positive	+0.1%	Caliwater named official hydration partner for the inaugural Enhanced Games event.
Mar 03	Athlete participation update	Positive	-0.1%	Olympic swimmer Hunter Armstrong confirmed as non‑enhanced competitor under standard testing.
Feb 12	SPAC S-4 filing	Positive	+0.0%	Form S‑4 filed for business combination to list Enhanced as Enhanced Group Inc.
Jan 26	Athlete medical clearance	Positive	+0.4%	Five additional athletes medically cleared for the May 24, 2026 Enhanced Games.

Pattern Detected

Recent news around athlete signings, partnerships, and the SPAC S-4 filing has generally seen small, mostly positive or flat price reactions, with one minor divergence on positive athlete news.

Recent Company History

Over the past few months, A Paradise/Enhanced has focused disclosures on building the inaugural Enhanced Games and advancing its SPAC combination. Announcements on Jan 26, Mar 3, Mar 4, and Mar 9 highlighted athlete clearances and sponsorships tied to the May 24, 2026 event, while the Feb 12 Form S‑4 filing formalized the business combination path. Today’s business update on the Live Enhanced consumer platform and peptide strategy extends that trajectory from event- and deal-focused news toward commercialization of performance and longevity products.

Market Pulse Summary

This announcement details the launch of Enhanced’s personalized performance medicine and supplement ...

Analysis

This announcement details the launch of Enhanced’s personalized performance medicine and supplement platform, expansion into peptide products, and an IRB-approved trial of 40 elite athletes tied to the May 24, 2026 Games. It reinforces a dual focus on competition and consumer products, building on prior SPAC and athlete updates. Key factors to watch include regulatory outcomes for the 14 peptides, traction of the Live Enhanced platform, and clinical findings that may differentiate its offerings.

Key Terms

hormone replacement therapy, peptide therapeutics, peptides, 503A pharmacies, +2 more

6 terms

hormone replacement therapy medical

"including hormone replacement therapy for women, hormone replacement therapy for men"

Hormone replacement therapy is a medical treatment that supplies the body with hormones it no longer makes enough of, like adding oil to an engine to restore smooth function. Investors care because demand, safety concerns, regulation, patents and pricing for these medicines and related devices can materially affect the revenues, costs and growth prospects of drugmakers, clinics and healthcare suppliers involved in producing or delivering them.

peptide therapeutics medical

"The global peptide therapeutics market is valued at approximately $52 billion today"

Peptide therapeutics are medicines made from short chains of amino acids—subunits of proteins—that act like targeted messengers to turn specific biological switches on or off. They matter to investors because they can offer high precision and potentially fewer side effects than conventional drugs, and success or failure in development, manufacturing scalability, and patent protection can sharply influence a biotech company's growth prospects and valuation; think of them as custom tools for precise problems.

peptides medical

"information and access to peptides.The Live Enhanced platform currently offers Sermorelin as a peptide"

Peptides are short chains of amino acids—the building blocks of proteins—that act like tiny messengers or tools in the body to trigger or block biological processes. Investors care because peptides are used as medicines, diagnostics, and research tools with potential for targeted treatments, often faster and cheaper to develop than large proteins; their commercial value depends on clinical results, manufacturing scalability, patent protection and regulatory approval.

503A pharmacies regulatory

"allowing licensed 503A pharmacies to compound them again"

503a pharmacies are licensed retail compounding pharmacies that make customized prescription medications for individual patients under specific federal and state rules, similar to a tailor who alters clothes to fit one person rather than a factory producing mass sizes. They matter to investors because regulatory compliance, quality controls and limits on who they can sell to affect a pharmacy’s revenue stability, legal risk and growth opportunities.

institutional review board (irb) medical

"sponsor of an independent Institutional Review Board (IRB) approved clinical trial with 40 elite athletes"

An institutional review board (IRB) is an independent committee that reviews and approves research involving people to make sure studies are safe, ethical, and that participants give informed consent. For investors, IRB approval is like a safety inspection for a company’s clinical program: it can reduce regulatory risk, affect how quickly trials start or proceed, and influence whether study results will be accepted by regulators, all of which can change a company’s value and outlook.

clinical trial medical

"approved clinical trial with 40 elite athletes being studied to assess the safety"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

AI-generated analysis. Not financial advice.

Personalized Performance Medicine & Supplement Platform Now Live with Proprietary Stronger & Longer Formulations

Announces Plans to Capitalize on Recent Indications Regarding the Reclassification of Certain Peptides

NEW YORK, March 18, 2026 /PRNewswire/ -- Enhanced, the elite sports competition and consumer products company, provided an important business update today announcing that its personalized performance medicine and supplement platform is now online. The company is ramping up its catalog of products as part of a phased rollout. The initial phase kicked off with the availability of Enhanced's Stronger and Longer proprietary blend supplement lines. The company has also made a range of performance and longevity products available at launch, including hormone replacement therapy for women, hormone replacement therapy for men, and other longevity protocols. These products mark the first step in the company's plan to become the leading provider of personalized enhancement products improving health, performance, and recovery.

"The launch of our performance and supplement business is yet another historic milestone in the company's history," said Maximilian Martin, Chief Executive Officer, Enhanced. "Our team has worked tirelessly to create a platform that offers products designed for each individual. This unmatched personalization along with proprietary data we gain from our athlete clinical trial provides a significant competitive advantage when compared to companies with standardized offerings."

Enhanced Plans Expansion of Product Catalog to Include Peptides

Additionally, the company confirmed it plans to expand its catalog to include a peptide product line in response to the recent indications that 14 peptide compounds currently on the U.S. Food & Drug Administration's Category 2 restricted list, may move to Category 1, therefore allowing licensed 503A pharmacies to compound them again. The global peptide therapeutics market is valued at approximately $52 billion today and projected to reach $87 billion by 2035.¹ This provides a critical revenue generation opportunity. Many of these popular peptide products align seamlessly within Enhanced's current longevity product catalog and the company is extremely well-positioned to capture meaningful consumer-facing demand as this market opens. The company is ready to become a go-to destination for people seeking information and access to peptides.

The Live Enhanced platform currently offers Sermorelin as a peptide, and plans to launch three additional peptides currently allowed to be compounded in the U.S., including Tesamorelin, Glutathione, and Oxytocin. The company could offer eight additional peptides based on regulatory approvals including: CJC-1295, Ipamorelin, Thymosin Alpha-1, TB-4, GHRP-2/6, Kisspeptin-10, Semax, and Selank. 

"Understanding how popular peptide usage has become globally we intend to invest heavily in this space," added Martin. "The data we collect from our sporting business informs our strategy and allows Enhanced to be the brand consumers think about for all their longevity and performance needs."

Enhanced consumer products and protocols are designed by a world-class expert team spanning our Medical and Scientific Commissions, providing the company with the most cutting edge leaders in the field including:

• Dr. Jonathann Kuo – one of the global leaders in the peptide space
• Dr. Abud Al Blakri – a leading authority in performance medicine, widely cited in the field

Enhanced Expands Female-Specific Performance Protocols

Additionally, Enhanced plans for its platform to include specifically designed protocols for women's performance, recovery, and hormonal health. The program is being developed in partnership with Elena Rueda Carrasco and Dr. Paulina Cecula, co-founders of Dama Health, who bring deep clinical expertise in female-specific enhancement medicine. These protocols bring together elite sports science and personalized clinical care in a way that has historically excluded women. In doing so, Enhanced will begin addressing a significant gap in both performance medicine and consumer health for women.

Advanced Research Creating Moat for Sustained Competitive Advantage

Currently, the company is the sponsor of an independent Institutional Review Board (IRB) approved clinical trial with 40 elite athletes being studied to assess the safety and tolerability of certain approved medical compounds on performance, as part of its inaugural Enhanced Games event on May 24th. This groundbreaking study, never before conducted, will give the company critical and proprietary data that no other provider can claim. While what helps elite athletes break world records is far too complex for the average person, the learnings gained through the clinical trial will help to continuously improve and differentiate our consumer products and prescription protocols - and this includes the peptide space.

1 According to Precedence Research

About Enhanced Business Combination Agreement

On November 26, 2025 Enhanced Ltd ("Enhanced" or the "Company") announced it entered into a definitive business combination agreement with A Paradise Acquisition Corp. ("A Paradise") (NASDAQ: APAD), a special purpose acquisition company (SPAC), with the intent to bring its global sports business to the U.S. public markets. The transaction is pending regulatory review by the United States Securities and Exchange Commission (SEC). (link)

About Enhanced Ltd

Enhanced is an elite sports competition and performance products company committed to giving athletes and people alike access to products that optimize their health, performance and recovery. The Enhanced Performance Product line provides consumers access to products, and protocols that optimize health, longevity and vitality. As a premium brand, Enhanced aims to revolutionize and lead the Performance Medicine category.

About The Enhanced Games

The Enhanced Games will champion scientific innovation and integrity in elite sporting competition. Enhanced believes in an objective, evidence-based approach to competition, one that celebrates athletic excellence and unlocks athletes' full potential. The Enhanced Games is not only creating a sporting event that is thrilling for spectators but also a beacon for scientific transparency and athlete welfare. By putting athletes first, it gives them the opportunity to reach their full potential and be compensated accordingly, all while ensuring their safety through rigorous medical supervision and scientific oversight. The inaugural Enhanced Games will take place on May 24, 2026 and will be held at a purpose-built competition complex at Resorts World Las Vegas. The Games will offer unprecedented financial incentives to athletes.

Contact
Chris Jones
Chief Communications Officer, Enhanced Games
media@enhanced.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/enhanced-provides-business-update-302716876.html

SOURCE Enhanced

FAQ

What did Enhanced (APAD) announce about its new platform on March 18, 2026?

Enhanced launched a personalized performance medicine and supplement platform on March 18, 2026. According to the company, the rollout began with proprietary Stronger and Longer supplement lines plus performance and longevity protocols for men and women.

Which peptides does Enhanced (APAD) currently offer and plan to add in 2026?

Enhanced currently offers Sermorelin and plans to add Tesamorelin, Glutathione, and Oxytocin in 2026. According to the company, up to eight additional peptides could be offered pending regulatory approvals and category reclassification.

How is Enhanced (APAD) using clinical trials to support its products?

Enhanced is sponsoring an IRB-approved clinical trial of 40 elite athletes to gather proprietary data. According to the company, trial learnings will inform personalization of consumer products and prescription protocols for performance and longevity.

What market opportunity did Enhanced (APAD) cite for peptide therapeutics?

Enhanced cited a peptide therapeutics market of approximately $52 billion today and projected to reach $87 billion by 2035. According to the company, this underpins a significant revenue opportunity if compounding access expands.

What are the regulatory risks for Enhanced (APAD)'s peptide strategy?

Peptide expansion is conditional on FDA category changes and compounding permissions, creating regulatory risk. According to the company, planned offerings depend on peptides moving from Category 2 to Category 1 before wider compounding.